Study shows frequently utilized serology test may not detect antibodies that might verify security versus reinfection of COVID-19

IMAGE: Raghu Kalluri, M.D., Ph.D.
view more

Credit: The University of Texas MD Anderson Cancer Center

HOUSTON– 2 different kinds of noticeable antibody reactions in SARS-CoV-2 (COVID-19) tell very various stories and may show methods to boost public health efforts versus the illness, according to researchers at The University of Texas MD Anderson Cancer Center. Antibodies to the SARS-CoV-2 spike protein receptor binding domain (S-RBD) are hypothesized to reduce the effects of virus infection, while the SARS-CoV-2 nucleocapsid protein (N-protein) antibody may frequently just suggest direct exposure to the virus, not protections against reinfection.

The results, released today in JCI Insight, emphasize findings from a quantitative serological enzyme-linked immunosorbent assay (ELISA) utilizing SARS-CoV-2 S-RBD and N-protein for the detection of distributing antibodies in 138 serial serum samples from confirmed COVID-19 hospitalized patients and 464 healthy and non-COVID-19 serum samples that were collected between June 2017 and June2020

.

Outcomes showed that 3%of healthy and non-COVID-19 samples gathered throughout the pandemic in Houston were favorable for the N-protein antibody, but just 1.6%of those had the S-RBD antibody. Of samples with the S-RBD antibody, 86%had reducing the effects of capability – suggesting they might avoid reinfection of COVID-19, but just 74%of samples with N-protein had neutralizing capacity.

” These findings suggest that detection of N-protein binding antibodies does not always correlate with presence of S-RBD neutralizing antibodies, and that the existence of the S-RBD antibody is the very best sign of any potential defense versus reinfection,” stated senior author Raghu Kalluri, M.D., Ph.D., teacher and chair of Cancer Biology. “We warn against the substantial use of N-protein based serology screening for determination of potential COVID-19 immunity, and our company believe that precise and trusted S-RBD serological testing is required to carefully identify people with neutralizing antibodies in order to help advance recovery efforts around the globe.”

At present, some commercially offered serological tests verify just the presence antibodies to the N-protein, with over 200 commercial and health center lab testing centers currently using these tests. While these tests indicate exposure to the virus, they do not seem to suggest resistance to reinfection. These findings repeat the need to educate on what an antibody test result mean for each client, and that public health efforts must focus on ways to motivate clients to continue alert safety precautions even with the presence of N-protein antibodies.

” In addition to serological assessment of the general population, we are confident these results will help in fast evaluation of the effectiveness of vaccine candidates as they are translated into the broader population,” stated lead author Kathleen McAndrews, Ph.D., postdoctoral fellow in Cancer Biology.

###

Luis L. Ostrosky-Zeichner, M.D., and Ramesh Papanna, M.D., of The University of Texas Health Science Center at Houston (UT Health) McGovern Medical School, contributed some samples to the research study. A full list of co-authors can be found in the paper.

About MD Anderson

The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world’s most appreciated centers concentrated on cancer client care, research, education and avoidance. The organization’s sole objective is to end cancer for clients and their families all over the world. MD Anderson is one of only 50 comprehensive cancer centers designated by the National Cancer Institute (NCI). MD Anderson is ranked No. 1 for cancer care in U.S. News & World Report’s “Best Healthcare facilities” study. It has actually ranked as one of the country’s leading 2 healthcare facilities for cancer care since the study began in 1990, and has ranked initially 16 times in the last 19 years. MD Anderson receives a cancer center assistance grant from the NCI of the National Institutes of Health (P30 CA016672).

Disclaimer: AAAS and EurekAlert!

Read More

https://covid19globalcases.com/study-shows-frequently-utilized-serology-test-may-not-detect-antibodies-that-might-verify-security-versus-reinfection-of-covid-19/